Latest

3 stories

Hide weekly roundups

Thursday, August 13

Cingulate reports Q2 2026 results, updates CTx-1301 CMC and NDA resubmission plans

Cingulate said it is finishing manufacturing work with its CDMO and plans to resubmit the CTx-1301 NDA to the FDA as promptly as practicable, with cash extending into mid-2027.

SEC filing

Thursday, July 23

PeopleCingulate Inc.

Cingulate eliminates chief legal officer role, Patel to depart in August

The company will not replace the position after its board voted to cut it on July 17, 2026.

SEC filing

Tuesday, July 14

PeopleCingulate Inc.

Cingulate holds annual meeting, restructures board, expands equity plan

Shareholders elected a director, ratified KPMG, and approved a 625,000-share increase to the equity incentive plan at the July 9, 2026 meeting.

SEC filing